Biogen Idec and Elan Will Host a Conference Call For the Investment Community

* Reuters is not responsible for the content in this press release.

Thu Jul 31, 2008 6:00pm EDT 

CAMBRIDGE, Mass. & DUBLIN, Ireland--(Business Wire)--
Biogen Idec Inc.(NASDAQ: BIIB) and Elan (NYSE: ELN) today
announced it will host a conference call for the Investment Community
to discuss the recent events related to TYSABRI(R) (natalizumab) on
Friday, August 1, 2008 at 8:30 a.m. ET/1:30 pm British Summer Time
(BST).

   To access the live webcast, please go to Biogen Idec's website at
www.biogenidec.com. Following the live webcast, an archived version of
the call will be available at the same URL.

   This event can be accessed by visiting Elan's website at
www.elan.com and clicking on the Investor Relations section, then on
the event icon. Following the live webcast, an archived version of the
call will be available at the same URL.

   About Biogen Idec

   Biogen Idec creates new standards of care in therapeutic areas
with high unmet medical needs. Founded in 1978, Biogen Idec is a
global leader in the discovery, development, manufacturing, and
commercialization of innovative therapies. Patients in more than 90
countries benefit from Biogen Idec's significant products that address
diseases such as lymphoma, multiple sclerosis, and rheumatoid
arthritis. For product labeling, press releases and additional
information about the company, please visit www.biogenidec.com.

   About Elan

   Elan Corporation, plc (NYSE: ELN) is a neuroscience-based
biotechnology company committed to making a difference in the lives of
patients and their families by dedicating itself to bringing
innovations in science to fill significant unmet medical needs that
continue to exist around the world. Elan shares trade on the New York,
London and Dublin Stock Exchanges. For additional information about
the company, please visit http://www.elan.com.

Biogen Idec
Investor Relations:
Eric Hoffman, 617-679-2812
or
Media Relations:
Naomi Aoki, 617-914-6524
or
Elan Corporation, plc
Investor Relations:
Chris Burns, 800-252-3526
or
David Marshall, 353-1-709-4444
or
Media Relations:
Jonathan Birt, 212-850-5664 or 44-20-7269-7205
or
Niamh Lyons, 353-1-663-3602

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.